Exicure Divestiture to GPCRT Inc. for $4.8M
Exicure, Inc. and its subsidiary GPCR USA entered into a definitive agreement to sell their GPC-100 (burixafor) program assets to South Korea-based GPCRT Inc. for approximately $4.8 million (KRW 6.5 billion) in cash. The divestiture includes intellectual property, clinical data, and the assignment of a 2025 license agreement, with the buyer assuming future milestone and royalty obligations. The sale is part of Exicure's ongoing evaluation of strategic alternatives to maximize stockholder value and strengthen its financial position.
- Value
- $4.8M
- Counterparty
- GPCRT Inc.